Literature DB >> 19614567

Form and flexibility in phosphoinositide 3-kinases.

Roger Williams1, Alex Berndt, Simon Miller, Wai-Ching Hon, Xuxiao Zhang.   

Abstract

PI3Ks (phosphoinositide 3-kinases) have important roles in a variety of cellular activities, including survival, proliferation, growth, shape, migration and intracellular sorting. Consistent with their function in cell survival and growth, the gene for the class Ialpha PI3K catalytic subunit is a common site of gain-of-function mutations in cancers. Ongoing structural studies of these enzymes and the complexes they make with their regulatory subunits have helped to clarify the mechanistic basis of this role in tumour development. The broad spectrum of biological activities associated with various isotypes of class I PI3Ks has led to an intense search for isotype-specific inhibitors as tools in mammalian cell biology and for therapeutic application. Structural studies of the class I PI3Ks suggest that flexibility may be a component of the catalytic cycle of the enzymes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614567     DOI: 10.1042/BST0370615

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  27 in total

Review 1.  Specific PI3K isoform modulation in heart failure: lessons from transgenic mice.

Authors:  Alessandra Ghigo; Fulvio Morello; Alessia Perino; Federico Damilano; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  TGF-β1 induces human aortic vascular smooth muscle cell phenotype switch through PI3K/AKT/ID2 signaling.

Authors:  Shui-Bo Zhu; Jian Zhu; Zi-Zi Zhou; Er-Ping Xi; Rong-Ping Wang; Yu Zhang
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

Review 3.  Resilience of biochemical activity in protein domains in the face of structural divergence.

Authors:  Dapeng Zhang; Lakshminarayan M Iyer; A Maxwell Burroughs; L Aravind
Journal:  Curr Opin Struct Biol       Date:  2014-06-19       Impact factor: 6.809

Review 4.  Crossroads of PI3K and Rac pathways.

Authors:  Carlo C Campa; Elisa Ciraolo; Alessandra Ghigo; Giulia Germena; Emilio Hirsch
Journal:  Small GTPases       Date:  2015-05-05

5.  Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.

Authors:  Simon J Mountford; Zhaohua Zheng; Krithika Sundaram; Ian G Jennings; Justin R Hamilton; Philip E Thompson
Journal:  ACS Med Chem Lett       Date:  2014-09-24       Impact factor: 4.345

6.  The p110δ subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice.

Authors:  Bit Na Kang; Sung Gil Ha; Xiao Na Ge; M Reza Hosseinkhani; Nooshin S Bahaie; Yana Greenberg; Malcolm N Blumenthal; Kamal D Puri; Savita P Rao; P Sriramarao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-03-16       Impact factor: 5.464

7.  p87 and p101 subunits are distinct regulators determining class IB phosphoinositide 3-kinase (PI3K) specificity.

Authors:  Aliaksei Shymanets; Kirsten Bucher; Sandra Beer-Hammer; Christian Harteneck; Bernd Nürnberg
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

Review 8.  RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

Review 9.  Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

Authors:  Sandra B Gabelli; Diana Mandelker; Oleg Schmidt-Kittler; Bert Vogelstein; L Mario Amzel
Journal:  Biochim Biophys Acta       Date:  2009-12-02

10.  The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.

Authors:  Alex Berndt; Simon Miller; Olusegun Williams; Daniel D Le; Benjamin T Houseman; Joseph I Pacold; Fabrice Gorrec; Wai-Ching Hon; Yi Liu; Christian Rommel; Pascale Gaillard; Thomas Rückle; Matthias K Schwarz; Kevan M Shokat; Jeffrey P Shaw; Roger L Williams
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.